In a healthcare landscape where innovation often takes center stage, there is a silent yet crucial challenge: ensuring that hospitals always have access to essential medicines, particularly in highly sensitive areas such as oncology. This is precisely the mission of Pharmavic Laboratories, a national company based in Málaga that has established itself as a reliable partner for the Spanish healthcare system.
Its Chief Executive Officer, Juan Antonio Vargas, explains that the company was created to fill a gap left by large multinational corporations: the withdrawal from the market of older, effective and widely used medicines whose low price makes them no longer profitable for major companies. The consequences of such withdrawal can be serious: patients arriving at the hospital only to find that the medication they need is not available.
Pharmavic works to prevent this from happening.
A laboratory with the highest level of authorization and nationwide presence
The company holds the highest authorization granted by the Spanish Agency of Medicines, allowing it to operate at full capacity within the hospital setting. Its products are currently available in more than 200 hospitals across Spain, and its portfolio includes six medicines, a number expected to reach 11 or 12 by the end of 2025.
In addition, the company has already begun its international expansion with a medicine registered in Portugal and plans to continue growing in the neighbouring country.
Ensuring that no patient goes untreated
One of the pillars of Pharmavic’s model is ensuring that hospitals have sufficient stock to avoid interruptions in treatment. Vargas notes that many oncology therapies combine innovative medicines with older, well‑established drugs that are essential to the clinical protocol. When the latter disappear from the market, the risk to the patient becomes clear.
Pharmavic focuses precisely on these medicines: drugs with decades of use, proven efficacy and a fundamental role in the treatment of various conditions, including colon cancer, whose global awareness day happened to coincide with the date of the interview.
Sustained Growth and New Developments
The company expects significant growth in the coming years, both in its product portfolio and in its team. It currently employs highly qualified professionals — pharmacists, biologists and economists — and plans to incorporate new profiles as its activity expands.
Among the projects currently under development is a medicine for cystic fibrosis, which is expected to be launched in 2029 or 2030.
An Ally of the Healthcare System
Although regulatory processes in the pharmaceutical sector are long and demanding — obtaining the license took two and a half years — Pharmavic has succeeded in establishing itself as a reliable partner for hospitals and the public healthcare system. Its direct relationship with hospital pharmacists and its ability to guarantee supply make it a key player in preventing shortages.
